Paul Glavine Acquires 100,000 Shares of Cybin (NASDAQ:HELP) Stock

Cybin Inc. (NASDAQ:HELP) insider Paul Glavine acquired 100,000 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were acquired at an average price of $12.47 per share, with a total value of $1,247,000.00. Following the acquisition, the insider owned 4,271,252 shares in the company, valued at approximately $53,262,512.44. The trade was a 2.40% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Paul Glavine also recently made the following trade(s):

• On Thursday, September 3rd, Paul Glavine bought 100,000 shares of Cybin stock. The shares were acquired at an average price of $11.78 per share, for a total transaction of $1,178,000.00.
• On Monday, August 31st, Paul Glavine bought 90,000 shares of Cybin stock. The shares were acquired at an average cost of $11.59 per share, for a total transaction of $1,043,100.00.

Cybin Stock Performance

Cybin stock opened at $12.97 on Friday. The stock has a 50-day moving average of $9.97 and a two-hundred day moving average of $6.89. Cybin Inc. has a one year low of $3.76 and a one year high of $14.35. The stock has a market cap of $980.66 million, a PE ratio of -4.29 and a beta of 0.63.

Cybin (NASDAQ:HELP) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). As a group, sell-side analysts predict that Cybin Inc. will post -2.95 EPS for the current fiscal year.

More Cybin News

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: Insider Paul Glavine bought 100,000 shares for approximately $1.25 million on September 8, increasing his direct ownership by 2.40%. Insider Eric H. L. So also purchased 100,000 shares for about $1.24 million, lifting his stake by 2.29%. These transactions follow additional purchases by both insiders in late August and early September, representing a notable pattern of open-market buying and likely supporting investor confidence. Eric So SEC filing Paul Glavine SEC filing
• Positive Sentiment: Cybin’s commercial operations are scheduled to receive investor exposure at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. CEO Michael Halstead is expected to participate in a fireside chat, potentially providing updates on the company’s psychedelic-based mental-health drug pipeline. Morgan Stanley conference announcement
• Neutral Sentiment: Reported short interest was zero shares with a zero-day days-to-cover ratio. However, the filing also showed an invalid “NaN” percentage change, making the data unreliable as an indicator of short-selling pressure.
• Negative Sentiment: Cybin remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.91 per share was worse than the expected $0.80 loss, and analysts project a full-year loss of approximately $2.95 per share. With no new trial result or regulatory approval reported, valuation and future financing needs remain important risks after the stock’s sharp advance.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HELP. Wells Fargo & Company started coverage on shares of Cybin in a research report on Monday, July 27th. They set an “overweight” rating and a $16.00 target price on the stock. Wall Street Zen raised shares of Cybin from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Finally, TD Cowen lifted their price objective on shares of Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $48.60.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HELP. Osaic Holdings Inc. lifted its position in Cybin by 46.7% during the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock valued at $63,000 after purchasing an additional 2,400 shares during the period. AXQ Capital LP purchased a new position in shares of Cybin during the 2nd quarter valued at about $75,000. Bank of America Corp DE lifted its holdings in shares of Cybin by 66.8% in the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock valued at $247,000 after buying an additional 11,790 shares during the period. Pale Fire Capital SE purchased a new stake in shares of Cybin in the second quarter worth about $1,015,000. Finally, Millennium Management LLC grew its holdings in Cybin by 1,388.5% during the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after acquiring an additional 959,448 shares during the period. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for the treatment of mental health conditions. The company combines drug discovery, clinical development and proprietary formulation technologies to design potentially more efficient and scalable psychedelic treatments.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin analog being studied for major depressive disorder, and CYB004, an investigational deuterated DMT molecule being evaluated for generalized anxiety disorder and other mental health indications.